Physics of Particle Beam and Hypofractionated Beam Delivery in NSCLC.
Where this comes from
- Record sourced from PubMed, PMID 33610274.
- Also identified by DOI 10.1016/j.semradonc.2020.11.004 and PMC identifier 7905707.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The dosimetric advantages of particle therapy lead to significantly reduced integral dose to normal tissues, making it an attractive treatment option for body sites such as the thorax. With reduced normal tissue dose comes the potential for dose escalation, toxicity reduction, or hypofractionation. While proton and heavy ion therapy have been used extensively for NSCLC, there are challenges in planning and delivery compared with X-ray-based radiation therapy. Particularly, range uncertainties compounded by breathing motion have to be considered. This article summarizes the current state of particle therapy for NSCLC with a specific focus on the impact of dosimetric uncertainties in planning and delivery.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Proton Therapy